Torbay and South Devon
NHS Foundation Trust

Email: foi.tsdft@nhs.net
Our Ref: TSD10909

21 October 2026

Dear Sir/Madam

Request for Information

We are writing to confirm that we have now completed our search for the information you requested.

A copy of the information is below:

How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	<5
Amivantamab Monotherapy	zero
Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only)	<5
Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel	<5
Atezolizumab monotherapy (subcutaneous injection only)	<5
Dabrafenib + Trametinib	zero
Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	<5
Durvalumab	5
Gemcitabine	zero monotherapy
Nintedanib + Docetaxel	<5
Nivolumab	zero
Osimertinib	13
Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	zero
Paclitaxel	zero monotherapy
Pembrolizumab Monotherapy	11
Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	<5
Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)	zero
Pemetrexed + Platinum (Carboplatin/Cisplatin)	<5
RET Inhibitors (Pralsetinib, Selpercatinib)	<5

Sotorasib	<5
Tepotinib	7
Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	<5
Other active systemic anti-cancer therapy	Docetaxel monotherapy <5 Encorafenib + Binimetinib <5 Gemcitabine + Carboplatin <5 Osimertinib, Pemetrexed and Carboplatin <5 Pemetrexed + Pembrolizumab <5 Carboplatin, Paclitaxel + RT <5
Palliative care only	46
Amivantamab with carboplatin and pemetrexed	zero
Cemiplimab with platinum-based chemotherapy	zero
Adagrasib	zero
Datopotamab deruxtecan	zero
Amivantamab with lazertinib	zero
Pembrolizumab subcutaneous injection	9

Low Numbers:
Where there are less than 5, we are unable to provide the exact information you require as this may enable the identification of our employees, members of the public or patients. This would constitute personal information and would be considered exempt under Section 40 of the Freedom of Information Act. Section 40 (FOI Act) provides an exemption to disclosure, where disclosure would contravene any of the Data Protection principles. This exemption is an absolute exemption that is not subject to the public interest test. Where the information relates to an individual who can be identified from that data, or from that data when added to other information, in the possession of, or likely to come into the possession of the data controller, this meets the definition of personal data as defined by the Data Protection Act.

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting.

If you wish to discuss any of the above, please contact us, quoting the FOI reference number above.

If you are unhappy with the way in which we have handled your request, please contact the Data Protection and Freedom of Information Lead in the first instance. If you wish to make a formal complaint, you should write to our Information Governance Team at Information Governance and Data Protection, Belmont Court, Torbay and South Devon NHS Foundation Trust, Torquay, TQ2 7AA or by email to tsdft.igteam@nhs.net

If you are not content with the outcome of your complaint or the internal review, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner will only make a decision once you have exhausted the complaints and/or internal review process provided by us. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or through this link https://ico.org.uk/global/contact-us/

Yours sincerely,

Freedom of Information Team